BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Patritumab Deruxtecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Patritumab Deruxtecan\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04965766-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20270411
DTEND;VALUE=DATE:20270412
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT04965766)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: Patritumab Deruxtecan (U3-1402) in Unresectable Locally Adv
 anced or Metastatic Breast Cancer\nEstimated primary completion: 11 April 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deru
 xtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04965766
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06383884-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06383884)
DESCRIPTION:Patritumab Deruxtecan\, phase 2.\nStudy: Patritumab Deruxtecan 
 in Patients With Solid Tumor Harboring an NRG1 Fusion\nEstimated primary c
 ompletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/patritumab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06383884
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06222489-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06222489)
DESCRIPTION:Patritumab Deruxtecan\, phase 2.\nStudy: Whole Body HER3 Quanti
 fication With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT\nEstim
 ated primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/patritumab-deruxtecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06222489
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06298084-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06298084)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: Dose-Expansion Modular Study To Explore the Safety\, Tole
 rability\, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinatio
 ns in Patients With Inoperable Advanced Breast Cancer (ABC) After Progress
 ion on T-DXd\nEstimated primary completion: September 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06298084
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445972-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20280509
DTEND;VALUE=DATE:20280510
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06445972)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Substudy 06D: Combin
 ation Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-34
 75-06D/Keymaker-U06)\nEstimated primary completion: 9 May 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06445972
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06596694-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20281207
DTEND;VALUE=DATE:20281208
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06596694)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Study of Patritumab 
 Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HE
 RTHENA-PanTumor02)\nEstimated primary completion: 7 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06596694
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Clinical Study of MK-1084 With Other Treatments for Non-small C
 ell Lung Cancer (MK-3475-01F)\nEstimated primary completion: 17 August 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07286149
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06469944-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20290912
DTEND;VALUE=DATE:20290913
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06469944)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: Substudy 06C: A Stud
 y of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy 
 in Participants With First-Line Locally Advanced Unresectable/Metastatic G
 astroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)\nEstimated prima
 ry completion: 12 September 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/patritumab-deruxtecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06469944
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06797635-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06797635)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Breast Cancer.\nStudy: Study 
 of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents i
 n Participants With High-Risk Early-Stage Triple-Negative or Hormone Recep
 tor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010\, HERTHENA-Brea
 st-03)\nEstimated primary completion: 31 December 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06797635
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172478-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20301119
DTEND;VALUE=DATE:20301120
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06172478)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 19 November 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06172478
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941272-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06941272)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2.\nStudy: A Study of Patrituma
 b Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid T
 umors (MK-9999-01C/LIGHTBEAM-U01)\nEstimated primary completion: 30 Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-d
 eruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06941272
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07701941-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07701941)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Study of Patritumab Deruxtecan (HER3-DXd) in Combinatio
 n With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive\, H
 ER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer\nEstimat
 ed primary completion: 1 January 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/patritumab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07701941
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembroliz
 umab (MK-3475) With or Without Chemotherapy When Used With Investigational
  Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung
  Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion:
  13 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pa
 tritumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04165070
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731907-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06731907)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of Pembrolizumab With or Without Chemotherapy in Combinatio
 n With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCL
 C) (MK-3475-01G/KEYMAKER U01)\nEstimated primary completion: 12 March 2032
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6731907
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06686394-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20320802
DTEND;VALUE=DATE:20320803
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT06686394)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Breast Cancer.\nStudy: Stud
 y of Patritumab Deruxtecan With Other Anticancer Agents in Participants Wi
 th HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Re
 moved (MK-1022-009)\nEstimated primary completion: 2 August 2032. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06686394
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060807-1981@assetmemo.bio
DTSTAMP:20261121T005003Z
DTSTART;VALUE=DATE:20330714
DTEND;VALUE=DATE:20330715
SUMMARY:Patritumab Deruxtecan: Phase 3 readout est. (NCT07060807)
DESCRIPTION:Patritumab Deruxtecan\, phase 3\, HR+/HER2- Metastatic Breast C
 ancer.\nStudy: A Clinical Study of Patritumab Deruxtecan to Treat Breast C
 ancer (MK-1022-016)\nEstimated primary completion: 14 July 2033. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07060807
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
